TD Cowen Upgrades Valneva (NASDAQ:VALN) to “Strong-Buy”

Valneva (NASDAQ:VALN) was upgraded by stock analysts at TD Cowen to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Several other brokerages have also recently weighed in on VALN. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a research note on Wednesday, April 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Finally, Guggenheim set a $11.00 target price on shares of Valneva in a research note on Thursday, April 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.98.

Valneva Stock Performance

Valneva stock opened at $5.59 on Tuesday. The company’s 50-day moving average price is $5.21 and its 200-day moving average price is $6.98. Valneva has a twelve month low of $4.75 and a twelve month high of $12.25. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The company has a market cap of $530.44 million, a PE ratio of -2.99 and a beta of 1.77.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The business had revenue of $35.77 million during the quarter. On average, equities research analysts forecast that Valneva will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva in the fourth quarter worth $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the third quarter valued at $124,000. XTX Topco Ltd purchased a new stake in shares of Valneva during the fourth quarter valued at $94,000. Finally, Marex Group plc bought a new position in shares of Valneva in the second quarter worth about $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.